Information:
Error:
ID
34289
Description
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin; ODM derived from: https://clinicaltrials.gov/show/NCT01713530
Link
https://clinicaltrials.gov/show/NCT01713530
Keywords
Versions (1)
- 1/16/19 1/16/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 16, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Diabetes NCT01713530
Eligibility Diabetes NCT01713530
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT01713530
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
diagnosis of type 2 diabetes mellitus at the discretion of the investigator for at least 26 weeks prior to screening (visit 1)
boolean
ID.2
Item
treatment with basal insulin for at least 12 weeks prior to randomisation with or without metformin, sulphonylurea (su)/glinide, dpp-4 inhibitors, alfa-glucosidase-inhibitors
boolean
ID.3
Item
hba1c 7.0% - 10.0%
boolean
ID.4
Item
body mass index (bmi) less than or equal to 40.0 kg/m^2
boolean
ID.5
Item
treatment with glucose-lowering agent(s) other than those stated in the inclusion criteria
boolean
ID.6
Item
stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
boolean
ID.7
Item
chronic disorder or disease which might jeopardise safety or compliance
boolean
ID.8
Item
malignant neoplasms
boolean
ID.9
Item
recurrent severe hypoglycaemia
boolean